Cargando…

The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action

The constitutive activation of B-cell receptor (BCR) signaling, together with the overexpression of the Bcl-2 family anti-apoptotic proteins, represents two hallmarks of chronic lymphocytic leukemia (CLL) that drive leukemia cell proliferation and sustain their survival. TG02 is a small molecule mul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Rong, Tsai, Jennifer, Thompson, Philip A., Chen, Yuling, Xiong, Ping, Liu, Chaomei, Burrows, Francis, Sivina, Mariela, Burger, Jan A., Keating, Michael J., Wierda, William G., Plunkett, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956145/ https://www.ncbi.nlm.nih.gov/pubmed/33714981 http://dx.doi.org/10.1038/s41408-021-00436-0

Ejemplares similares

P637: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINUTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL
por: Burger, Jan, et al.
Publicado: (2023)

The BET Inhibitor GS-5829 Targets Chronic Lymphocytic Leukemia Cells and Their Supportive Microenvironment
por: Kim, Ekaterina, et al.
Publicado: (2019)

Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells
por: Chen, Rong, et al.
Publicado: (2022)

PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL.
por: Burger, J., et al.
Publicado: (2022)

The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells
por: Fiorcari, Stefania, et al.
Publicado: (2013)

ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2)
por: Jiang, Y, et al.
Publicado: (2016)

Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)
por: Al-Kali, Aref, et al.
Publicado: (2010)

STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells
por: Rozovski, Uri, et al.
Publicado: (2018)

STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells
por: Rozovski, Uri, et al.
Publicado: (2018)

Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab
por: Jain, Punit, et al.
Publicado: (2016)

Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic
por: Balakrishnan, Kumudha, et al.
Publicado: (2016)

Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells
por: Modi, Prexy, et al.
Publicado: (2017)

Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukemia
por: Zhang, Wan, et al.
Publicado: (2012)

Regulation of Mcl-1 Expression in Context to Bone Marrow Stromal Microenvironment in Chronic Lymphocytic Leukemia()
por: Balakrishnan, Kumudha, et al.
Publicado: (2014)

Prognostication of DNA Damage Response Protein Expression Patterns in Chronic Lymphocytic Leukemia
por: Griffen, Ti’ara L., et al.
Publicado: (2023)

PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells
por: Cervantes-Gomez, Fabiola, et al.
Publicado: (2019)

The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells()()
por: Vangapandu, Hima V., et al.
Publicado: (2017)

Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells
por: Vangapandu, Hima V., et al.
Publicado: (2018)

Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02
por: von Achenbach, Caroline, et al.
Publicado: (2020)

STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells
por: Rozovski, Uri, et al.
Publicado: (2021)

The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View
por: Tambaro, Francesco Paolo, et al.
Publicado: (2021)

Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells
por: Pallis, Monica, et al.
Publicado: (2016)

Centimeter-Level Orbit Determination for TG02 Spacelab Using Onboard GNSS Data
por: Li, Kai, et al.
Publicado: (2018)

Ruxolitinib for symptom control in patients with Chronic Lymphocytic leukemia: A Phase II Trial
por: Jain, Preetesh, et al.
Publicado: (2017)

Interferon-β sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02
por: Lohmann, Birthe, et al.
Publicado: (2020)

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
por: Landau, Dan A., et al.
Publicado: (2017)

Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells
por: Rozovski, Uri, et al.
Publicado: (2013)

Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042
por: Accart, Nathalie, et al.
Publicado: (2013)

1719. Incidence and Characterization of Invasive Fungal Infections (IFIs) in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib (IBR)
por: Frei, Michael, et al.
Publicado: (2019)

The CXCR4–STAT3–IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide
por: Shaim, Hila, et al.
Publicado: (2018)

Differences in electron beam dosimetry using two commercial ionization chambers and the TG‐21 protocol: Another reason to switch to TG‐51
por: Followill, David S., et al.
Publicado: (2003)

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
por: Yi, Xue, et al.
Publicado: (2022)

TIPS-12 PHASE I CLINICAL STUDY OF TG02 CAPSULE IN THE TREATMENT OF RECURRENT HIGH-GRADE GLIOMAS WITH FAILED TMZ TREATMENT
por: Guo, Chengcheng, et al.
Publicado: (2023)

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
por: Burger, Jan A., et al.
Publicado: (2016)

The influence of thyroid status, serum Tg, TSH, and TgAb on FNA‐Tg in cervical metastatic lymph nodes of papillary thyroid carcinoma
por: Sun, Jingjing, et al.
Publicado: (2021)

A Two-Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia
por: Schweighofer, Carmen D., et al.
Publicado: (2011)

Using TG1 and TG2's with cycle lengths > 32 s
por: Beetham, D
Publicado: (1983)

Immunization With a DNA Vaccine Cocktail Encoding TgPF, TgROP16, TgROP18, TgMIC6, and TgCDPK3 Genes Protects Mice Against Chronic Toxoplasmosis
por: Zhang, Nian-Zhang, et al.
Publicado: (2018)

Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia
por: Aslan, Burcu, et al.
Publicado: (2022)

Protective immunity induced by DNA vaccine containing TgGRA35, TgGRA42, and TgGRA43 against Toxoplasma gondii infection in Kunming mice
por: Shi, Youbo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6snh0qph1vjjcf9hl2su8af0g0